Skye Bioscience (SKYE) Competitors $4.95 -0.56 (-10.16%) (As of 11/15/2024 08:55 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SKYE vs. CRMD, TECX, ABVX, ORIC, PROK, PHAT, ANAB, ALT, IGMS, and OCSShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include CorMedix (CRMD), Tectonic Therapeutic (TECX), ABIVAX Société Anonyme (ABVX), ORIC Pharmaceuticals (ORIC), ProKidney (PROK), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Altimmune (ALT), IGM Biosciences (IGMS), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. CorMedix Tectonic Therapeutic ABIVAX Société Anonyme ORIC Pharmaceuticals ProKidney Phathom Pharmaceuticals AnaptysBio Altimmune IGM Biosciences Oculis Skye Bioscience (NASDAQ:SKYE) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Does the MarketBeat Community favor SKYE or CRMD? CorMedix received 11 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 73.33% of users gave CorMedix an outperform vote. CompanyUnderperformOutperformSkye BioscienceOutperform Votes11100.00% Underperform VotesNo VotesCorMedixOutperform Votes2273.33% Underperform Votes826.67% Is SKYE or CRMD more profitable? Skye Bioscience's return on equity of -45.78% beat CorMedix's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -45.78% -37.44% CorMedix N/A -79.21%-64.68% Which has more risk & volatility, SKYE or CRMD? Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Do analysts rate SKYE or CRMD? Skye Bioscience currently has a consensus price target of $18.67, suggesting a potential upside of 277.10%. CorMedix has a consensus price target of $15.20, suggesting a potential upside of 47.14%. Given Skye Bioscience's higher possible upside, equities analysts plainly believe Skye Bioscience is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00CorMedix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SKYE or CRMD? In the previous week, Skye Bioscience had 2 more articles in the media than CorMedix. MarketBeat recorded 6 mentions for Skye Bioscience and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.96 beat Skye Bioscience's score of 0.31 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in SKYE or CRMD? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by company insiders. Comparatively, 5.2% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, SKYE or CRMD? Skye Bioscience has higher earnings, but lower revenue than CorMedix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$37.65MN/AN/ACorMedix$60K10,447.07-$46.34M-$0.81-12.75 SummarySkye Bioscience beats CorMedix on 8 of the 13 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.17M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E RatioN/A4.9166.6713.57Price / SalesN/A376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book1.989.686.475.93Net Income-$37.65M$154.43M$119.73M$225.73M7 Day Performance-13.31%-9.46%-5.13%-1.34%1 Month Performance17.02%-7.27%-2.71%1.15%1 Year Performance184.48%28.13%31.08%24.02% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience1.5685 of 5 stars$4.95-10.2%$18.67+277.1%+224.6%$150.17MN/A0.0011News CoverageHigh Trading VolumeCRMDCorMedix2.7427 of 5 stars$11.00-3.1%N/A+171.8%$667.48M$60,000.00-13.5830Short Interest ↓TECXTectonic Therapeutic3.6912 of 5 stars$43.26-7.4%N/AN/A$637.22MN/A-7.34120Analyst ForecastHigh Trading VolumeABVXABIVAX Société Anonyme3.0751 of 5 stars$9.96-2.2%N/A-14.1%$630.37MN/A0.0061Short Interest ↓News CoverageGap DownORICORIC Pharmaceuticals4.1783 of 5 stars$8.83-14.0%N/A+29.8%$622.87MN/A-4.9180Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpPROKProKidney2.5099 of 5 stars$2.15+3.9%N/A+37.8%$622.79MN/A-3.913Earnings ReportPHATPhathom Pharmaceuticals2.8188 of 5 stars$9.09-6.8%N/A+19.8%$621.55M$26.27M-1.60110Positive NewsANABAnaptysBio2.5896 of 5 stars$20.17-2.8%N/A+33.2%$613.77M$17.16M-3.32100Analyst ForecastALTAltimmune2.2862 of 5 stars$8.46-11.1%N/A+222.5%$600.91M$409,000.00-5.4550Earnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionNews CoverageGap DownIGMSIGM Biosciences4.6905 of 5 stars$10.10-9.4%N/A+64.4%$599.12M$2.91M-2.77190Earnings ReportShort Interest ↓OCSOculis2.9193 of 5 stars$14.71-0.1%N/A+44.1%$595.76M$980,000.00-7.622Short Interest ↓ Related Companies and Tools Related Companies CRMD Alternatives TECX Alternatives ABVX Alternatives ORIC Alternatives PROK Alternatives PHAT Alternatives ANAB Alternatives ALT Alternatives IGMS Alternatives OCS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SKYE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SKYE Stock Alerts